|
|
1.
|
NANO SOMA
| Application Number |
1690162 |
| Status |
Registered |
| Filing Date |
2022-07-22 |
| Registration Date |
2022-07-22 |
| Owner |
NANORX INC. (USA)
|
| NICE Classes ? |
05 - Pharmaceutical, veterinary and sanitary products
|
Goods & Services
Analgesic and muscle relaxant nutraceutical preparations;
anti-diabetic nutraceuticals; cardiovascular nutraceuticals;
nutraceutical preparations for the treatment of gout;
nutraceutical preparations and substances for the treatment
of gastro-intestinal diseases; nutraceutical preparations
and substances for the treatment of infectious diseases,
blood disorders, pain, inflammation, sepsis, alopecia,
obesity and cognitive disorders; nutraceutical preparations
and substances for the treatment of viral, metabolic,
endocrine, musculoskeletal, cardiovascular, cardiopulmonary,
genitourinary, sexual dysfunction, oncological,
hepatological, ophthalmic, respiratory, neurological,
gastrointestinal, hormonal, dermatological, psychiatric and
immune system related diseases and disorders; nutraceutical
preparations for inhalation for the treatment of pulmonary
hypertension; nutraceutical preparations for the prevention
and treatment of disorders of the nervous system, the immune
system, the cardio-vascular system, the metabolic system,
the respiratory system, the musculo-skeletal system, the
genitourinary system; nutraceutical preparations for the
treatment of inflammatory disorders; nutraceutical
preparations for use in dermatology, oncology, hematology
and in tissue and organ transplantation, in ophthalmology
and for gastroenterological disorders; nutraceutical
preparations for the prevention and treatment of ocular
disorders or diseases, bacteria-based diseases or disorders,
autoimmune diseases or disorders, kidney diseases or
disorders, and diabetes; nutraceutical preparations for the
prevention of diabetes; nutraceutical preparations for the
treatment of eye diseases and conditions; nutraceutical
preparations for the treatment of heart rhythm disorders;
nutraceutical preparations for the treatment of hormonal
disorders and the prevention of osteoporosis; nutraceutical
preparations for the treatment of infectious diseases;
nutraceutical preparations for the treatment of
hypertension; nutraceutical preparations for treating
allergic rhinitis and asthma; nutraceutical preparations for
treating diabetes; nutraceutical preparations for treating
skin disorders; nutraceutical preparations for use in
urology; nutraceutical preparations, namely, a blood
clotting aid and delivery system for use in human and
veterinary medicine; nutraceutical products for
ophthalmological use; nutraceutical products for the
treatment of bone diseases; nutraceutical products for the
treatment of joint disease; nutraceutical products for the
treatment of viral and infectious diseases; nutraceutical
preparations for the treatment of cancer; nutraceutical
products for treating respiratory diseases and asthma;
nutraceutical solutions used in dialysis; nutraceuticals,
namely, lipid lowering agents; plant extracts for medical,
veterinary and nutraceutical purposes; therapeutic
nutraceuticals for the treatment of obesity.
|
2.
|
METADICHOL
| Application Number |
1675241 |
| Status |
Registered |
| Filing Date |
2022-04-22 |
| Registration Date |
2022-04-22 |
| Owner |
NANORX INC. (USA)
|
| NICE Classes ? |
05 - Pharmaceutical, veterinary and sanitary products
|
Goods & Services
Analgesic and muscle relaxant nutraceutical preparations;
anti-diabetic nutraceuticals; cardiovascular nutraceuticals;
nutraceutical preparations for the treatment of gout;
nutraceutical preparations and substances for the treatment
of gastro-intestinal diseases; nutraceutical preparations
and substances for the treatment of infectious diseases,
blood disorders, pain, inflammation, sepsis, alopecia,
obesity and cognitive disorders; nutraceutical preparations
and substances for the treatment of viral, metabolic,
endocrine, musculoskeletal, cardiovascular, cardiopulmonary,
genitourinary, sexual dysfunction, oncological,
hepatological, ophthalmic, respiratory, neurological,
gastrointestinal, hormonal, dermatological, psychiatric and
immune system related diseases and disorders; nutraceutical
preparations for inhalation for the treatment of pulmonary
hypertension; nutraceutical preparations for the prevention
and treatment of disorders of the nervous system, the immune
system, the cardio-vascular system, the metabolic system,
the respiratory system, the musculo-skeletal system, the
genitourinary system; nutraceutical preparations for the
treatment of inflammatory disorders; nutraceutical
preparations for use in dermatology, oncology, hematology
and in tissue and organ transplantation, in ophthalmology
and for gastroenterological disorders; nutraceutical
preparations for the prevention and treatment of ocular
disorders or diseases, bacteria-based diseases or disorders,
autoimmune diseases or disorders, kidney diseases or
disorders, and diabetes; nutraceutical preparations for the
prevention of diabetes; nutraceutical preparations for the
treatment of eye diseases and conditions; nutraceutical
preparations for the treatment of heart rhythm disorders;
nutraceutical preparations for the treatment of hormonal
disorders and the prevention of osteoporosis; nutraceutical
preparations for the treatment of infectious diseases;
nutraceutical preparations for the treatment of
hypertension; nutraceutical preparations for treating
allergic rhinitis and asthma; nutraceutical preparations for
treating diabetes; nutraceutical preparations for treating
skin disorders; nutraceutical preparations for use in
urology; nutraceutical preparations, namely, a blood
clotting aid and delivery system for use in human and
veterinary medicine; nutraceutical products for
ophthalmological use; nutraceutical products for the
treatment of bone diseases; nutraceutical products for the
treatment of joint disease; nutraceutical products for the
treatment of viral and infectious diseases; nutraceutical
preparations for the treatment of cancer; nutraceutical
products for treating respiratory diseases and asthma;
nutraceutical solutions used in dialysis; nutraceuticals,
namely, lipid lowering agents; plant extracts for medical,
veterinary and nutraceutical purposes; therapeutic
nutraceuticals for the treatment of obesity.
|
3.
|
METADICHOL
| Application Number |
213297800 |
| Status |
Registered |
| Filing Date |
2021-09-13 |
| Registration Date |
2022-07-13 |
| Owner |
Nanorx Inc. (USA)
|
| NICE Classes ? |
05 - Pharmaceutical, veterinary and sanitary products
|
Goods & Services
(1) Analgesic and muscle relaxant nutraceutical preparations; Anti-diabetic nutraceuticals; Cardiovascular nutraceuticals; Nutraceutical preparations for the treatment of gout; Nutraceutical preparations and substances for the treatment of gastro-intestinal diseases; Nutraceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Nutraceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Nutraceutical preparations for inhalation for the treatment of pulmonary hypertension; Nutraceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system; Nutraceutical preparations for the treatment of inflammatory disorders; Nutraceutical preparations for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Nutraceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Nutraceutical preparations for the prevention of diabetes; Nutraceutical preparations for the treatment of eye diseases and conditions; Nutraceutical preparations for the treatment of heart rhythm disorders; Nutraceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Nutraceutical preparations for the treatment of infectious diseases; Nutraceutical preparations for the treatment of hypertension; Nutraceutical preparations for treating allergic rhinitis and asthma; Nutraceutical preparations for treating diabetes; Nutraceutical preparations for treating skin disorders; Nutraceutical preparations for use in urology; Nutraceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; Nutraceutical products for ophthalmological use; Nutraceutical products for the treatment of bone diseases; Nutraceutical products for the treatment of joint disease; Nutraceutical products for the treatment of viral and infectious diseases; Nutraceutical preparations for the treatment of cancer; Nutraceutical products for treating respiratory diseases and asthma; Nutraceutical solutions used in dialysis; Nutraceuticals, namely, lipid lowering agents; Plant extracts for medical, veterinary and nutraceutical purposes for maintaining and boosting the immune system; Therapeutic nutraceuticals for the treatment of obesity; Analgesic and muscle relaxant pharmaceutical preparations; Anti-diabetic pharmaceuticals; Cardiovascular pharmaceuticals; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system, for the treatment of inflammatory disorders, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical preparations for the prevention of diabetes; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of hypertension; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in urology; Pharmaceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; Pharmaceutical products for ophthalmological use; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for the treatment of joint disease; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical solutions used in dialysis; Pharmaceuticals, namely, lipid lowering agents; Plant extracts for medical, veterinary and pharmaceutical purposes for maintaining and boosting the immune system; Therapeutic pharmaceutical for the treatment of obesity
|
4.
|
NANO SOMA
| Application Number |
213298300 |
| Status |
Registered |
| Filing Date |
2021-09-13 |
| Registration Date |
2022-07-13 |
| Owner |
Nanorx Inc. (USA)
|
| NICE Classes ? |
05 - Pharmaceutical, veterinary and sanitary products
|
Goods & Services
(1) Nutraceuticals for use as a dietary supplement for boosting the immune system
|
5.
|
NANO SOMA
| Serial Number |
90896879 |
| Status |
Registered |
| Filing Date |
2021-08-23 |
| Registration Date |
2022-09-13 |
| Owner |
NANORX INC. ()
|
| NICE Classes ? |
05 - Pharmaceutical, veterinary and sanitary products
|
Goods & Services
Nutraceuticals for use as a dietary supplement
|
6.
|
NANO SOMA
| Application Number |
018537187 |
| Status |
Registered |
| Filing Date |
2021-08-19 |
| Registration Date |
2021-12-15 |
| Owner |
Nanorx, Inc. (USA)
|
| NICE Classes ? |
05 - Pharmaceutical, veterinary and sanitary products
|
Goods & Services
Nutraceuticals for use as a dietary supplement.
|
7.
|
METADICHOL
| Application Number |
018535307 |
| Status |
Registered |
| Filing Date |
2021-08-19 |
| Registration Date |
2021-12-24 |
| Owner |
Nanorx, Inc. (USA)
|
| NICE Classes ? |
05 - Pharmaceutical, veterinary and sanitary products
|
Goods & Services
Analgesic and muscle relaxant nutraceutical preparations; anti-diabetic nutraceuticals; Cardiovascular nutraceuticals; Nutraceutical preparations for the treatment of gout; Nutraceutical preparations and substances for the treatment of gastro-intestinal diseases; Nutraceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Nutraceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Nutraceutical preparations for inhalation for the treatment of pulmonary hypertension; Nutraceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system; Nutraceutical preparations for the treatment of inflammatory disorders; Nutraceutical preparations for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Nutraceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Nutraceutical preparations for the prevention of diabetes; Nutraceutical preparations for the treatment of eye diseases and conditions; Nutraceutical preparations for the treatment of heart rhythm disorders; Nutraceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Nutraceutical preparations for the treatment of infectious diseases; Nutraceutical preparations for the treatment of hypertension; Nutraceutical preparations for treating allergic rhinitis and asthma; Nutraceutical preparations for treating diabetes; Nutraceutical preparations for treating skin disorders; Nutraceutical preparations for use in urology; Nutraceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; Nutraceutical products for ophthalmological use; Nutraceutical products for the treatment of bone diseases; Nutraceutical products for the treatment of joint disease; Nutraceutical products for the treatment of viral and infectious diseases; Nutraceutical preparations for the treatment of cancer; Nutraceutical products for treating respiratory diseases and asthma; Nutraceutical solutions used in dialysis; Nutraceuticals, namely, lipid lowering agents; Plant extracts for medical, veterinary and nutraceutical purposes; Therapeutic nutraceuticals for the treatment of obesity.
|
8.
|
NANO-OJAS
| Application Number |
018537185 |
| Status |
Registered |
| Filing Date |
2021-08-19 |
| Registration Date |
2021-12-24 |
| Owner |
Nanorx, Inc. (USA)
|
| NICE Classes ? |
05 - Pharmaceutical, veterinary and sanitary products
|
Goods & Services
Analgesic and muscle relaxant nutraceutical preparations; Anti-diabetic nutraceuticals; Cardiovascular nutraceuticals; Nutraceutical preparations for the treatment of gout; Nutraceutical preparations and substances for the treatment of gastro-intestinal diseases; Nutraceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Nutraceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Nutraceutical preparations for inhalation for the treatment of pulmonary hypertension; Nutraceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system; Nutraceutical preparations for the treatment of inflammatory disorders; Nutraceutical preparations for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Nutraceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Nutraceutical preparations for the prevention of diabetes; Nutraceutical preparations for the treatment of eye diseases and conditions; Nutraceutical preparations for the treatment of heart rhythm disorders; Nutraceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Nutraceutical preparations for the treatment of infectious diseases; Nutraceutical preparations for the treatment of hypertension; Nutraceutical preparations for treating allergic rhinitis and asthma; Nutraceutical preparations for treating diabetes; Nutraceutical preparations for treating skin disorders; Nutraceutical preparations for use in urology; Nutraceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; Nutraceutical products for ophthalmological use; Nutraceutical products for the treatment of bone diseases; Nutraceutical products for the treatment of joint disease; Nutraceutical products for the treatment of viral and infectious diseases; Nutraceutical preparations for the treatment of cancer; Nutraceutical products for treating respiratory diseases and asthma; Nutraceutical solutions used in dialysis; Nutraceuticals, namely, lipid lowering agents; Plant extracts for medical, veterinary and nutraceutical purposes; Therapeutic nutraceuticals for the treatment of obesity.
|
9.
|
NANO-OJAS
| Serial Number |
87073835 |
| Status |
Registered |
| Filing Date |
2016-06-16 |
| Registration Date |
2016-12-20 |
| Owner |
NANORX INC. (USA)
|
| NICE Classes ? |
05 - Pharmaceutical, veterinary and sanitary products
|
Goods & Services
Analgesic and muscle relaxant nutraceutical preparations; Anti-diabetic nutraceuticals; Cardiovascular nutraceuticals; Nutraceutical preparations for the treatment of gout; Nutraceutical preparations and substances for the treatment of gastro-intestinal diseases; Nutraceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Nutraceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Nutraceutical preparations for inhalation for the treatment of pulmonary hypertension; Nutraceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system; Nutraceutical preparations for the treatment of inflammatory disorders; Nutraceutical preparations for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Nutraceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Nutraceutical preparations for the prevention of diabetes; Nutraceutical preparations for the treatment of eye diseases and conditions; Nutraceutical preparations for the treatment of heart rhythm disorders; Nutraceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Nutraceutical preparations for the treatment of infectious diseases; Nutraceutical preparations for the treatment of hypertension; Nutraceutical preparations for treating allergic rhinitis and asthma; Nutraceutical preparations for treating diabetes; Nutraceutical preparations for treating skin disorders; Nutraceutical preparations for use in urology; Nutraceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; Nutraceutical products for ophthalmological use; Nutraceutical products for the treatment of bone diseases; Nutraceutical products for the treatment of joint disease; Nutraceutical products for the treatment of viral and infectious diseases; Nutraceutical preparations for the treatment of cancer; Nutraceutical products for treating respiratory diseases and asthma; Nutraceutical solutions used in dialysis; Nutraceuticals, namely, lipid lowering agents; Plant extracts for medical, veterinary and nutraceutical purposes; Therapeutic nutraceuticals for the treatment of obesity
|
10.
|
METADICHOL
| Serial Number |
87017926 |
| Status |
Registered |
| Filing Date |
2016-04-28 |
| Registration Date |
2016-12-20 |
| Owner |
NANORX INC. ()
|
| NICE Classes ? |
05 - Pharmaceutical, veterinary and sanitary products
|
Goods & Services
Analgesic and muscle relaxant nutraceutical preparations; Anti-diabetic nutraceuticals; Cardiovascular nutraceuticals; Nutraceutical preparations for the treatment of gout; Nutraceutical preparations and substances for the treatment of gastro-intestinal diseases; Nutraceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Nutraceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Nutraceutical preparations for inhalation for the treatment of pulmonary hypertension; Nutraceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system; Nutraceutical preparations for the treatment of inflammatory disorders; Nutraceutical preparations for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Nutraceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Nutraceutical preparations for the prevention of diabetes; Nutraceutical preparations for the treatment of eye diseases and conditions; Nutraceutical preparations for the treatment of heart rhythm disorders; Nutraceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Nutraceutical preparations for the treatment of infectious diseases; Nutraceutical preparations for the treatment of hypertension; Nutraceutical preparations for treating allergic rhinitis and asthma; Nutraceutical preparations for treating diabetes; Nutraceutical preparations for treating skin disorders; Nutraceutical preparations for use in urology; Nutraceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; Nutraceutical products for ophthalmological use; Nutraceutical products for the treatment of bone diseases; Nutraceutical products for the treatment of joint disease; Nutraceutical products for the treatment of viral and infectious diseases; Nutraceutical preparations for the treatment of cancer; Nutraceutical products for treating respiratory diseases and asthma; Nutraceutical solutions used in dialysis; Nutraceuticals, namely, lipid lowering agents; Plant extracts for medical, veterinary and nutraceutical purposes; Therapeutic nutraceuticals for the treatment of obesity
|
11.
|
METADICHOL.RTM. LIQUID AND GEL NANOPARTICLE FORMULATIONS
| Document Number |
02894370 |
| Status |
In Force |
| Filing Date |
2014-03-11 |
| Open to Public Date |
2014-09-25 |
| Grant Date |
2016-01-12 |
| Owner |
NANORX, INC. (USA)
|
| Inventor |
Raghavan, Palayakotai R.
|
Abstract
The present invention provides methods of regulating physiological and metabolic parameters and of treating diseases by administering metadichol to a subject in need of such regulation and/or treatment. Metadichol can be administered as a liquid or gel formulation.
IPC Classes ?
- A61K 9/10 - DispersionsEmulsions
- A61K 9/14 - Particulate form, e.g. powders
- A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
- A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
- A61P 17/00 - Drugs for dermatological disorders
- A61P 37/00 - Drugs for immunological or allergic disorders
|
12.
|
METADICHOL R LIQUID AND GEL NANOPARTICLE FORMULATIONS
| Application Number |
US2014023777 |
| Publication Number |
2014/150609 |
| Status |
In Force |
| Filing Date |
2014-03-11 |
| Publication Date |
2014-09-25 |
| Owner |
NANORX, INC. (USA)
|
| Inventor |
Raghavan, Palayakotai, R.
|
Abstract
The present invention provides methods of regulating physiological and metabolic parameters and of treating diseases by administering metadichol to a subject in need of such regulation and/or treatment. Metadichol can be administered as a liquid or gel formulation.
|
13.
|
Metadichol® liquid and gel nanoparticle formulations
| Application Number |
14205243 |
| Grant Number |
09006292 |
| Status |
In Force |
| Filing Date |
2014-03-11 |
| First Publication Date |
2014-09-18 |
| Grant Date |
2015-04-14 |
| Owner |
NanoRx, Inc. (USA)
|
| Inventor |
Raghavan, Palayakotai R.
|
Abstract
The present invention provides methods of regulating physiological and metabolic parameters and of treating diseases by administering metadichol to a subject in need of such regulation and/or treatment. Metadichol can be administered as a liquid or gel formulation.
IPC Classes ?
- A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
- B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
- A61K 9/14 - Particulate form, e.g. powders
- A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
|
14.
|
POLICOSANOL NANOPARTICLES
| Document Number |
02844073 |
| Status |
In Force |
| Filing Date |
2011-08-16 |
| Open to Public Date |
2012-03-01 |
| Grant Date |
2015-10-13 |
| Owner |
NANORX, INC. (USA)
|
| Inventor |
Raghavan, Palayakotai R.
|
Abstract
The present invention provides nanoparticulate policosanol, and octacosanol formulations including these particles, as a well as methods of using the particles and formulations for treatment and prophylaxis of various diseases and conditions.
IPC Classes ?
- A61K 9/14 - Particulate form, e.g. powders
- A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
- A61P 3/06 - Antihyperlipidemics
- A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
|
15.
|
POLICOSANOL NANOPARTICLES
| Application Number |
US2011047951 |
| Publication Number |
2012/027159 |
| Status |
In Force |
| Filing Date |
2011-08-16 |
| Publication Date |
2012-03-01 |
| Owner |
NANORX, INC. (USA)
|
| Inventor |
Raghavan, Palayakotai, R.
|
Abstract
The present invention provides nanoparticulate policosanol, and octacosanol formulations including these particles, as a well as methods of using the particles and formulations for treatment and prophylaxis of various diseases and conditions.
|
16.
|
Policosanol nanoparticles
| Application Number |
13211132 |
| Grant Number |
09034383 |
| Status |
In Force |
| Filing Date |
2011-08-16 |
| First Publication Date |
2012-02-23 |
| Grant Date |
2015-05-19 |
| Owner |
NanoRx, Inc. (USA)
|
| Inventor |
Raghavan, Palayakotai R.
|
Abstract
The present invention provides nanoparticulate policosanol, and octacosanol formulations including these particles, as a well as methods of using the particles and formulations for treatment and prophylaxis of various diseases and conditions.
IPC Classes ?
- A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
- A61K 31/355 - Tocopherols, e.g. vitamin E
- B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- A61K 9/14 - Particulate form, e.g. powders
- A61K 9/51 - Nanocapsules
|
17.
|
POLICOSANOL NANOPARTICLES
| Document Number |
02788777 |
| Status |
In Force |
| Filing Date |
2010-01-21 |
| Open to Public Date |
2010-08-26 |
| Grant Date |
2015-02-17 |
| Owner |
NANORX, INC. (USA)
|
| Inventor |
Raghavan, Palayakotai R.
|
Abstract
The present invention provides nanoparticulate policosanol, formulations including these particles, as a well as methods of using the particles and formulations for treatment and prophylaxis of various diseases and conditions.
IPC Classes ?
- A61K 9/14 - Particulate form, e.g. powders
- A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
|
18.
|
POLICOSANOL NANOPARTICLES
| Application Number |
US2010021684 |
| Publication Number |
2010/096231 |
| Status |
In Force |
| Filing Date |
2010-01-21 |
| Publication Date |
2010-08-26 |
| Owner |
NANORX, INC. (USA)
|
| Inventor |
Raghavan, Palayakotai, R.
|
Abstract
The present invention provides nanoparticulate policosanol, formulations including these particles, as a well as methods of using the particles and formulations for treatment and prophylaxis of various diseases and conditions.
IPC Classes ?
- A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
- A61K 9/14 - Particulate form, e.g. powders
|
19.
|
Policosanol nanoparticles
| Application Number |
12691706 |
| Grant Number |
08722093 |
| Status |
In Force |
| Filing Date |
2010-01-21 |
| First Publication Date |
2010-08-26 |
| Grant Date |
2014-05-13 |
| Owner |
NanoRx, Inc. (USA)
|
| Inventor |
Raghavan, Palayakotai R.
|
Abstract
The present invention provides nanoparticulate policosanol, formulations including these particles, as a well as methods of using the particles and formulations for treatment and prophylaxis of various diseases and conditions.
IPC Classes ?
- A61K 9/14 - Particulate form, e.g. powders
- A61K 9/50 - Microcapsules
- A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
|
|